Uncategorized

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

2025-01-07T13:06:02-06:00

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco’s proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M. [...]

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody2025-01-07T13:06:02-06:00

Vertex Enters Duchenne Therapy Market with $1B Acquisition of Exonics

2019-08-26T10:12:52-05:00

Move over, Sarepta Therapeutics, Solid Biosciences, PTC Therapeutics and Pfizer. Vertex Pharmaceuticals, which dominates the cystic fibrosis drug market, has just entered the multibillion-dollar race to find effective treatments — and maybe even cures — for two other rare diseases: Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The Boston-based giant will [...]

Vertex Enters Duchenne Therapy Market with $1B Acquisition of Exonics2019-08-26T10:12:52-05:00

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

2019-08-09T11:37:18-05:00

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline Acquisition Includes Novel Late-Stage Renal Cell Carcinoma Candidate, PT2977 Business Wire KENILWORTH, N.J. & DALLAS -- May 21, 2019 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc. today announced that the companies have entered into a definitive agreement [...]

Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline2019-08-09T11:37:18-05:00

Peloton Therapeutics Secures $150 Million in Series E Financing

2019-08-09T11:25:48-05:00

- Proceeds to advance oral HIF-2α inhibitor, PT2977, into Phase 3 trial in advanced renal cell carcinoma – - Financing led by RA Capital Management - DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., a drug discovery and development company advancing first-in-class oral medicines for cancer and other serious conditions, today announced the closing of an oversubscribed $150 [...]

Peloton Therapeutics Secures $150 Million in Series E Financing2019-08-09T11:25:48-05:00

CoStim Pharmaceuticals, Inc. Acquired by Novartis

2019-03-06T23:43:28-06:00

BOSTON, Feb. 17, 2014 /PRNewswire/ -- MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. ("CoStim") has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune [...]

CoStim Pharmaceuticals, Inc. Acquired by Novartis2019-03-06T23:43:28-06:00
Go to Top